Professor of Medicine and Microbiology/Immunology
Rheumatology
Dr. David Wofsy, MD
|
|
Give Review
David Wofsy works in the field of Rheumatology. He attended University of California San Diego School of Medicine. University of California San Diego School of Medicine has a rank of 17 in research and a 19 in primary care He received awards:"America's Top Doctors" and "Super Doctor". David Wofsy is a published doctor. He published 88 publications, including: 'Opportunities for future biological therapy in SLE.'
Publications
- In Memoriam: Ephraim P. Engleman, MD, 1911-2015.
- Crossing the Atlantic - The Euro-Lupus nephritis regimen in North America.
- Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe Systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised tr...
- Recent progress in conventional and biologic therapy for Systemic lupus erythematosus.
- Comparison of alternative primary outcome measures for use in a lupus nephritis trial.
- Abatacept for lupus nephritis: alternative definitions of complete response support conflicting conclusions.
- Interleukin 6 promotes murine lupus in NZB/NZW F1 mice.
- Treatment of murine lupus with monoclonal antibodies to lymphocyte function-associated antigen-1: dose-dependent inhibition of autoantibody production and blockade of ...
- T-Cell homeostasis: implications in HIV infection .
- Treatment of murine lupus with anti-CD4 monoclonal antibodies.
- Recent advances in the treatment of rheumatic Diseases: new approaches to immunotherapy.
- Blind T-Cell homeostasis in CD4-deficient mice.
- The CD28-B7 costimulatory pathway and its role in autoimmune Disease.
- Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways.
- Enhanced lymphoproliferation and diminished autoimmunity in CD4-deficient MRL/lpr mice.
- On the horizon: clinical trials of new immunosuppressive strategies for autoimmune Diseases.
- Opportunities for future biological therapy in SLE.
- Effects of anti-B7 monoclonal antibodies on humoral immune responses.
- The effect on immunoglobulin glycosylation of altering in vivo production of immunoglobulin G.
- Nephritogenic cytokines and Disease in MRL-Fas(lpr) kidneys are dependent on multiple T-cell subsets.
- Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with Systemic lupus erythematosus.
- Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide.
- Treatment of autoimmunity by inhibition of T Cell costimulation.
- The immune tolerance network and rheumatic Disease: immune tolerance comes to the clinic.
- Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with Systemic lupus erythematosus: results of a multicenter, phase Ib, double-blin...
- A quality indicator set for Systemic lupus erythematosus.
- Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest.
- Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis.
- Systemic lupus erythematosus clinical trials-an interim analysis.
- Regulatory T cells as therapeutic targets in rheumatoid Arthritis.
- Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study.
- Nonrenal Disease activity following mycophenolate mofetil or intravenous cyclophosphamide as induction treatment for lupus nephritis: findings in a multicenter, prospe...
- Biologic therapy for Systemic lupus erythematosus.
- Connective tissue Diseases: Belimumab for systemic lupus erythematosus: breaking through?
- Plagiarism on personal statements: a disturbing symptom of a broader trend.
- Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide.
- A 24-week, randomized, double-blind, placebo-controlled, parallel group study of the efficacy of oral SCIO-469, a p38 mitogen-activated protein kinase inhibitor, in pa...
- Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis.
- Treatment of systemic lupus erythematosus by inhibition of T Cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial.
- Living in a different world.
- Inhibition of T cell costimulation: an emerging therapeutic strategy for autoimmune rheumatic Diseases.
- Clinical trial design in Systemic lupus erythematosus.
- Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (A...
- Block and tackle: CTLA4Ig takes on lupus.
- Coccidioidomycosis of the thyroid.
- Development of murine lupus in CD4-depleted NZB/NZW mice. Sustained inhibition of residual CD4+ T Cells is required to suppress autoimmunity.
- The role of T-Cell subsets in the response to anti-CD3 monoclonal antibodies.
- Tumorigenesis mediated by an antigen receptor.
- F(ab')2 anti-CD4 and intact anti-CD4 monoclonal antibodies inhibit the accumulation of CD4+ T Cells, CD8+ T Cells, and B Cells in the kidneys of lupus-prone NZB/NZW mice.
- CD4 antibody therapy in Systemic lupus erythematosus.
- Regulation of immunity by anti-T-Cell antibodies.
- Effects of recombinant murine tumor necrosis factor-alpha on immune function.
- Induction of immune tolerance during administration of monoclonal antibody to L3T4 does not depend on depletion of L3T4+ Cells.
- Treatment of murine lupus with F(ab')2 fragments of monoclonal antibody to L3T4. Suppression of autoimmunity does not depend on T helper Cell depletion.
- Effects of selective depletion of L3T4+ T-lymphocytes on herpes simplex virus encephalitis.
- Treatment of murine lupus with monoclonal antibody to L3T4. II. Effects on immunohistopathology of thymus, spleen, and lymph node.
- New therapies for the rheumatic Diseases.
- Chronic therapy with recombinant tumor necrosis factor-alpha in autoimmune NZB/NZW F1 mice.
- Rejection of skin grafts and generation of cytotoxic T Cells by mice depleted of L3T4+ Cells.
- Proliferation of Ly-1 B Cells in autoimmune NZB and (NZB x NZW)F1 mice.
- The role of Lyt-2+ T Cells in the regulation of autoimmunity in murine lupus.
- Treatment of autoimmune Diseases with monoclonal antibodies.
- Anti-Ly-1 antibody induces interleukin 2 release from T Cells.
- Administration of monoclonal anti-T Cell antibodies retards murine lupus in BXSB mice.
- Induction of immune tolerance by administration of monoclonal antibody to L3T4.
- Analysis of the function of L3T4+ T Cells by in vivo treatment with monoclonal antibody to L3T4.
- Administration of F(ab')2 fragments of monoclonal antibody to L3T4 inhibits humoral immunity in mice without depleting L3T4+ Cells.
- Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4.
- Inhibition of humoral immunity in vivo by monoclonal antibody to L3T4: studies with soluble antigens in intact mice.
- Treatment of murine lupus with monoclonal antibody to L3T4. I. Effects on the distribution and function of lymphocyte subsets and on the histopathology of autoimmune d...
- Selective manipulation of the immune response in vivo by monoclonal antibodies.
- New approaches to treating Systemic lupus erythematosus.
- Treatment of murine lupus with monoclonal anti-T Cell antibody.
- Strategies for treating autoimmune Disease with monoclonal antibodies.
- Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.
- Antibodies to Tp67 and Tp44 augment and sustain proliferative responses of activated T Cells.
- The proliferating Cells in autoimmune MRL/lpr mice lack L3T4, an antigen on "helper" T Cells that is involved in the response to class II major histocompatibility anti...
- Treatment of autoimmune MRL/Ipr mice with monoclonal antibody to Thy-1.2: a single injection has sustained effects on lymphoproliferation and renal Disease.
- Interleukin-2 deficiency, genes, and Systemic lupus erythematosus.
- Monocytosis in the BXSB model for Systemic lupus erythematosus.
- Effects of castration and sex hormones on immune clearance and autoimmune Disease in MRL/Mp-lpr/lpr and MRL/Mp-+/+ mice.
- Interleukin 2 deficiency is a common feature of autoimmune mice.
- Deficient interleukin 2 activity in MRL/Mp and C57BL/6J mice bearing the lpr gene.
- Interleukin-2 deficiency in murine Systemic lupus erythematosus.
- Thymic influences on autoimmunity in MRL-lpr mice.
- Culture-negative septic Arthritis and bacterial endocarditis. Diagnosis by synovial biopsy.
- Treatment of murine lupus with CTLA4Ig.
Schools
University of California At San Diego
Ucsf Hosps
Conditions Treated
- Arthritis
- Bursitis
- Calcium Pyrophosphate Dihydrate Deposition Disease (CPPD)
- Degenerative Disc Disease
- View All
Doctors Specialties
- Rheumatology
Accepted Insurances
Awards
- America's Top Doctors
- Super Doctor
Education
-
UCSF -
University of California San Diego School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
San Francisco VA Medical Center -
UCSF Medical Center
Helpful Reviews
Similar Doctors
|
|
Dr. Claire M. Targoff, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. John B. Imboden Jr., MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Maria C. Dall'Era, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Barbara K. Finck, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Tamiko R. Katsumoto, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew M. Reimert, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Mary E. Margaretten, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Pedro J. Ruiz, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew D. Cascino, MD
This Doctor is OpenDoctor Recommended.
|